Language:

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Han, Bihua ; Song, Yufei ; Li, Changgui ; Yang, Wanqi ; Ma, Qingxia ; Jiang, Zhiwei ; Li, Minjie ; Lian, Xiaojuan ; Jiao, Wenbin ; Wang, Lei ; Shu, Qun ; Wu, Zhiwei ; Zhao, Yuliang ; Li, Qi ; Gao, Qiang

The Lancet infectious diseases, 2021-12, Vol.21 (12), p.1645-1653 [Peer Reviewed Journal]

United States: Elsevier Ltd

Full text available

Citations Cited by

Actions
1. Add to e-Shelf
2. Remove from e-Shelf
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
Author: Han, Bihua ; Song, Yufei ; Li, Changgui ; Yang, Wanqi ; Ma, Qingxia ; Jiang, Zhiwei ; Li, Minjie ; Lian, Xiaojuan ; Jiao, Wenbin ; Wang, Lei ; Shu, Qun ; Wu, Zhiwei ; Zhao, Yuliang ; Li, Qi ; Gao, Qiang
Subjects: Adjuvants, Immunologic - administration & dosage ; Adjuvants, Immunologic - adverse effects ; Adolescent ; Adolescents ; Adverse events ; Age ; Alum ; Aluminum ; Aluminum hydroxide ; Antibodies ; Antibodies, Neutralizing - blood ; Antibodies, Viral - blood ; Asymptomatic ; Child ; Child, Preschool ; Children ; China ; Clinical trials ; Coronaviruses ; COVID-19 ; COVID-19 - immunology ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - administration & dosage ; COVID-19 Vaccines - adverse effects ; COVID-19 Vaccines - immunology ; Deactivation ; Disease control ; Dosage ; Dose-Response Relationship, Immunologic ; Double-Blind Method ; Double-blind studies ; Female ; Humans ; Immunization ; Immunogenicity ; Immunogenicity, Vaccine ; Infections ; Infectious diseases ; Injection ; Injections, Intramuscular ; Life sciences ; Male ; Multisystem inflammatory syndrome in children ; Pain ; Pandemics ; Population ; R&D ; Randomization ; Research & development ; Safety ; SARS-CoV-2 - immunology ; Seroconversion ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Side effects ; Teenagers ; Vaccination ; Vaccines ; Vaccines, Inactivated - administration & dosage ; Vaccines, Inactivated - adverse effects ; Vaccines, Inactivated - immunology ; Vectors (Biology) ; Viral diseases ; Viruses
Is Part Of: The Lancet infectious diseases, 2021-12, Vol.21 (12), p.1645-1653
Notes: Contributed equally to the manuscript
Description: A vaccine against SARS-CoV-2 for children and adolescents will play an important role in curbing the COVID-19 pandemic. Here we aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in children and adolescents aged 3–17 years. We did a double-blind, randomised, controlled, phase 1/2 clinical trial of CoronaVac in healthy children and adolescents aged 3–17 years old at Hebei Provincial Center for Disease Control and Prevention in Zanhuang (Hebei, China). Individuals with SARS-CoV-2 exposure or infection history were excluded. Vaccine (in 0·5 mL aluminum hydroxide adjuvant) or aluminum hydroxide only (alum only, control) was given by intramuscular injection in two doses (day 0 and day 28). We did a phase 1 trial in 72 participants with an age de-escalation in three groups and dose-escalation in two blocks (1·5 μg or 3·0 μg per injection). Within each block, participants were randomly assigned (3:1) by means of block randomisation to receive CoronaVac or alum only. In phase 2, participants were randomly assigned (2:2:1) by means of block randomisation to receive either CoronaVac at 1·5 μg or 3·0 μg per dose, or alum only. All participants, investigators, and laboratory staff were masked to group allocation. The primary safety endpoint was adverse reactions within 28 days after each injection in all participants who received at least one dose. The primary immunogenicity endpoint assessed in the per-protocol population was seroconversion rate of neutralising antibody to live SARS-CoV-2 at 28 days after the second injection. This study is ongoing and is registered with ClinicalTrials.gov, NCT04551547. Between Oct 31, 2020, and Dec 2, 2020, 72 participants were enrolled in phase 1, and between Dec 12, 2020, and Dec 30, 2020, 480 participants were enrolled in phase 2. 550 participants received at least one dose of vaccine or alum only (n=71 for phase 1 and n=479 for phase 2; safety population). In the combined safety profile of phase 1 and phase 2, any adverse reactions within 28 days after injection occurred in 56 (26%) of 219 participants in the 1·5 μg group, 63 (29%) of 217 in the 3·0 μg group, and 27 (24%) of 114 in the alum-only group, without significant difference (p=0·55). Most adverse reactions were mild and moderate in severity. Injection site pain was the most frequently reported event (73 [13%] of 550 participants), occurring in 36 (16%) of 219 participants in the 1·5 μg group, 35 (16%) of 217 in the 3·0 μg group, and two (2%) in the alum-only group. As of June 12, 2021, only one serious adverse event of pneumonia has been reported in the alum-only group, which was considered unrelated to vaccination. In phase 1, seroconversion of neutralising antibody after the second dose was observed in 27 of 27 participants (100·0% [95% CI 87·2–100·0]) in the 1·5 μg group and 26 of 26 participants (100·0% [86·8-100·0]) in the 3·0 μg group, with the geometric mean titres of 55·0 (95% CI 38·9–77·9) and 117·4 (87·8–157·0). In phase 2, seroconversion was seen in 180 of 186 participants (96·8% [93·1–98·8]) in the 1·5 μg group and 180 of 180 participants (100·0% [98·0–100·0]) in the 3·0 μg group, with the geometric mean titres of 86·4 (73·9–101·0) and 142·2 (124·7–162·1). There were no detectable antibody responses in the alum-only groups. CoronaVac was well tolerated and safe and induced humoral responses in children and adolescents aged 3–17 years. Neutralising antibody titres induced by the 3·0 μg dose were higher than those of the 1·5 μg dose. The results support the use of 3·0 μg dose with a two-immunisation schedule for further studies in children and adolescents. The Chinese National Key Research and Development Program and the Beijing Science and Technology Program.
Publisher: United States: Elsevier Ltd
Language: English

Links

View this record in MEDLINE/PubMed

Back to results list

Previous Result 6 Next Go to Next page

Implemented by: Social Network Logos:

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Han, Bihua ; Song, Yufei ; Li, Changgui ; Yang, Wanqi ; Ma, Qingxia ; Jiang, Zhiwei ; Li, Minjie ; Lian, Xiaojuan ; Jiao, Wenbin ; Wang, Lei ; Shu, Qun ; Wu, Zhiwei ; Zhao, Yuliang ; Li, Qi ; Gao, Qiang

United States: Elsevier Ltd

Searching Remote Databases, Please Wait